SC life sciences news of note fro your reading pleasure is now live! see more
This edition of SCBIO's semi-monthly newsletter is chock full of great information, including next week's eagerly anticipated webinar featuring top elected officials on SC's path forward from COVID, the "Slow the Spread" PSA campaign from BCBSSC and SCHA, highlights on companies stepping up in tough times, late-breaking news and more. Read the entire thing by clicking here!
KIYATEC Adds Clinical and Reimbursement Experience to Board as Clinical Testing Validation ProgressesKIYATEC adds to its Board of Directors see more
KIYATEC, Inc. today announced the appointment of Bruce Nash, MD, MBA, to its Board of Directors. Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital and medical group practice settings. Currently, he serves as Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans. During his career, Dr. Nash has held executive leadership positions in both managed care (Kaiser Permanente, Capital District Physicians’ Health Plan) and healthcare (Northern Berkshire Health System, North Adams Regional Hospital) organizations.
Dr. Nash serves on the boards of the Blue Cross Blue Shield Foundation and the Network for Excellence in Health Innovation (NEHI), while also serving on the Board of Strategic Advisors at the Excel Venture Management Fund and the Clinical Advisory Group at the Blue Venture Fund. He is a board-certified physician who completed his residency training at Duke University. Bruce earned his MBA in Health Sector Management from Duke University's Fuqua School of Business.
“We are delighted to welcome Dr. Nash to KIYATEC’s Board of Directors,” said Robert Silverman, Chairman of the Board of Directors of KIYATEC. “Bruce’s relevant experience and vision as both a clinician and an expert in managed care will provide tremendous value as KIYATEC moves forward in the development of our predictive clinical tests to improve cancer patient care and outcomes.”
The addition of Dr. Nash to the KIYATEC Board of Directors comes as the company’s evidence development efforts continue to gain momentum:
- 3D-PREDICT Study (NCT03561207) of clinical tests to predict pre-treatment drug response to drug therapies for ovarian cancer and high-grade glioma continues to add study sites and enroll patients
- Pilot study publication entitled, “Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer,” was recognized this spring by Scientific Reports (Nature Research) as being one of its Top 100 cancer papers of 2019 (of >1,000 published)
- Emerging evidence of I/O (immuno-oncology) drug response characterization to be presented via multiple posters at AACR in June
About KIYATEC, Inc.
KIYATEC leverages its proprietary ex vivo 3D cell culture platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina Engaging Members With Telehealth OptionBlueCross BlueShield, BlueChoice HealthPlan of SC are urging patients to use telehealth see more
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan of South Carolina are urging people to consider telehealth for their next non-emergency room doctor visit. Members can use the service for behavioral health, urgent care and lactation consultation.
Both companies are advocating the option during Telehealth Awareness Week Oct. 15 – 19, 2018, the annual observance of telehealth programs and services available in communities around the state.
“Many health care visits can be conducted without being in person, such as by video,” said BlueCross Chief Medical Officer Matt Bartels, M.D. “While telehealth does not replace your relationship with your primary care physician it is a useful avenue for increasing access and convenience, which our members have told us is very important to them. Telehealth is especially useful in reducing unnecessary emergency room visits.”
Available anytime on a computer, tablet or mobile phone, Blue CareOnDemand— the BlueCross and BlueChoice telehealth platform — uses video to securely connect members with a physician who will review their symptoms, ask and answer questions, make diagnoses and prescribe medications, if appropriate. All the providers are U.S. board-certified physicians and licensed health care professionals.
During Telehealth Awareness Week, BlueCross will post telehealth information across its social media channels. Followers can expect topics such as explaining how a telehealth visit works, member testimonials and simplifying use of telehealth.
BlueCross and BlueChoice members can register for the service, which was launched in January 2016, at www.BlueCareOnDemandSC.com, or they can search for Blue CareOnDemand in the App Store or Google Play.
Many members have downloaded the app and those who have not are urged to do so now because of emergency uncertainties, including the upcoming flu season.